> Detailanzeige

Cornelissen, Jan J.; van der Holt, Bronno; Verhoef, Gregor E. G.; van 't Veer, Mars B.; van Oers, Marinus H. J.; Schouten, Harry C.; Ossenkoppele, Gert; Sonneveld, Pieter; Maertens, Johan; van Marwijk Kooy, Marinus; Schaafsma, Martijn R.; Wijermans, Pierre W.; Biesma, Douwe H.; Wittebol, Shulamit; Voogt, Paul J.; Baars, Joke W.; Zachée, Pierre; Verdonck, Leo F.; Löwenberg, Bob; Dekker, Adriaan W.

Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison
  • Beteiligte: Cornelissen, Jan J.; van der Holt, Bronno; Verhoef, Gregor E. G.; van 't Veer, Mars B.; van Oers, Marinus H. J.; Schouten, Harry C.; Ossenkoppele, Gert; Sonneveld, Pieter; Maertens, Johan; van Marwijk Kooy, Marinus; Schaafsma, Martijn R.; Wijermans, Pierre W.; Biesma, Douwe H.; Wittebol, Shulamit; Voogt, Paul J.; Baars, Joke W.; Zachée, Pierre; Verdonck, Leo F.; Löwenberg, Bob; Dekker, Adriaan W.
  • Erschienen: American Society of Hematology, 2009
  • Erschienen in: Blood
  • Sprache: Englisch
  • DOI: 10.1182/blood-2008-07-168625
  • ISSN: 0006-4971; 1528-0020
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:p>While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still disputed in adult patients with standard-risk ALL. We evaluated outcome of patients with ALL in first complete remission (CR1), according to a sibling donor versus no-donor comparison. Eligible patients (433) were entered in 2 consecutive, prospective studies, of whom 288 (67%) were younger than 55 years, in CR1, and eligible to receive consolidation by either an autologous SCT or an allo-SCT. Allo-SCT was performed in 91 of 96 patients with a compatible sibling donor. Cumulative incidences of relapse at 5 years were, respectively, 24 and 55% for patients with a donor versus those without a donor (hazard ratio [HR], 0.37; 0.23-0.60; P &lt; .001). Nonrelapse mortality estimated 16% (± 4) at 5 years after allo-SCT. As a result, disease-free survival (DFS) at 5 years was significantly better in the donor group: 60 versus 42% in the no-donor group (HR: 0.60; 0.41-0.89; P = .01). After risk-group analysis, improved outcome was more pronounced in standard-risk patients with a donor, who experienced an overall survival of 69% at 5 years (P = .05). In conclusion, standard-risk ALL patients with a sibling donor may show favorable survival following SCT, due to both a strong reduction of relapse and a modest nonrelapse mortality. This trial is registered with http://www.trialregister.nl under trial ID NTR228.</jats:p>
  • Zugangsstatus: Freier Zugang